Eurand NV Company Description
Holding company Eurand has pharmaceutical operations in Europe and North America. The company specializes in the development and commercialization of pharmaceutical and biopharmaceutical products using its drug delivery technologies. The company co-markets products through collaborations, such as Amrix for muscle spasms (with Cephalon). Eurand's lead product candidate, Zentase (formerly EUR-1008), is awaiting FDA approval for the treatment of exocrine pancreatic insufficiency. The company also has other products under development independently and with partner pharmaceutical firms. Warburg Pincus and affiliates control 77% of the company's shares.
View the Comprehensive Company Description for Eurand NV
The Company Description provides a historical perspective of Eurand NV's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Eurand NV's evolution in the marketplace.
